These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 30391576)

  • 1. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
    Ferrara MG; Martini M; D'Argento E; Forcella C; Vita E; Di Noia V; Sperduti I; Bilotta M; Ribelli M; Damiano P; Cannella A; Stefani A; Pilotto S; Carbone C; Piro G; Milella M; Tortora G; Bria E
    Clin Lung Cancer; 2021 Jul; 22(4):351-360. PubMed ID: 33558194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.
    Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
    J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.
    Chevallier M; Tsantoulis P; Addeo A; Friedlaender A
    Cancer Genomics Proteomics; 2020; 17(5):597-603. PubMed ID: 32859638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The concomitant gene alterations impact the therapeutic efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with epidermal growth factor receptor sensitive mutation].
    Li JM; Hu J; Bai CX; Zhang Y; Xu XB; Wang XD; Ding N
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):778-782. PubMed ID: 30347549
    [No Abstract]   [Full Text] [Related]  

  • 12. Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
    Deng LL; Gao G; Deng HB; Wang F; Wang ZH; Yang Y
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2613-2624. PubMed ID: 31463717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
    Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
    ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
    Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
    JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
    Cheng Y; Ma L; Liu Y; Zhu J; Xin Y; Liu X; Wang Y; Zhang T; Yang C; Wang S; Cui H; Zhang L; Dai J; Shao L; Lin J; Ye J; Liu H
    Lung Cancer; 2020 Jul; 145():63-70. PubMed ID: 32408134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis.
    Wei Y; Shen K; Lv T; Wang X; Li C; Fan H; Lv Y; Liu H; Song Y
    Lung Cancer; 2018 Nov; 125():43-50. PubMed ID: 30429037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.